财务数据和关键指标变化 - 公司第三季度收入为1.39亿美元，同比增长15% [16] - 调整后的EBITDA为2400万美元，同比增长8% [16] - 调整后的净收入为500万美元，同比增长10% [19] 各条业务线数据和关键指标变化 - 外科解决方案收入增长18%，包括超声波和骨移植替代品的双位数增长 [17] - 疼痛治疗收入增长18%，主要得益于Durolane的品牌认知度和临床差异化 [17] - 恢复疗法销售增长6%，Exogen的增长加速 [18] 各个市场数据和关键指标变化 - 国际市场收入同比增长10%，主要受Durolane和超声波业务部分恢复的推动 [18] 公司战略和发展方向和行业竞争 - 公司专注于加速收入增长、提高盈利能力和增强流动性 [7][14] - 计划通过战略投资和市场教育来推动超声波手术的市场渗透 [9] - 预计在2025年实现低于3倍的净杠杆率 [20] 管理层对经营环境和未来前景的评论 - 管理层对第四季度的增长持谨慎乐观态度，预计将受到去年同期的影响 [25] - 对于2025年，管理层预计将继续保持正向增长，尽管面临更高的比较基数 [30] 其他重要信息 - 公司计划在2024年将净销售额预期提高至5.62亿至5.67亿美元 [21] - 调整后的每股收益预期在0.40至0.42美元之间 [22] - 公司已达成以2500万美元出售其先进康复业务的协议 [12] 问答环节所有提问和回答 问题: 关于2024年指导的更多信息 - 管理层表示，第四季度的增长将受到去年同期的影响，特别是Exogen的单次有利因素 [25] 问题: 关于疼痛业务的前景 - 管理层对疼痛业务在第四季度的表现持乐观态度，预计将继续保持增长 [28] 问题: 关于2025年的增长预期 - 管理层表示，尽管2025年的比较基数将更高，但仍然预计将保持正向增长 [30] 问题: 关于竞争对手的关注 - 管理层对竞争对手的动态表示没有担忧，认为公司在临床差异化和市场执行方面具有优势 [39] 问题: 关于国际市场的前景 - 管理层对国际市场的增长潜力持乐观态度，认为未来几年将成为公司增长的重要贡献者 [41]

业绩总结 - 第三季度收入为1.39亿美元，同比增长15%[6] - 调整后的EBITDA为2400万美元，同比增长8%[6] - 调整后的毛利率为74.7%，较去年下降10个基点[8] - 疼痛治疗业务收入同比增长18%[9] - 外科解决方案收入同比增长16%[10] - 预计2024年净销售额将在5.62亿至5.67亿美元之间[13] - 第三季度现金流为1000万美元，现金余额为4300万美元[12] - 净杠杆率在第三季度降至3.5倍，预计在2025年之前降至3倍以下[12] - 调整后的每股收益预计在0.40至0.42美元之间[13] 财务数据 - 2024年9月28日的持续经营净亏损为5421万美元，2023年9月30日为8791万美元，2023年12月31日为1.21亿美元[15] - 2024年9月28日的调整后EBITDA为23557万美元，2023年9月30日为21735万美元，2023年12月31日为88862万美元[15] - 2024年9月28日的利息支出为9532万美元，2023年9月30日为10115万美元，2023年12月31日为40676万美元[15] - 2024年9月28日的折旧和摊销费用为12275万美元，2023年9月30日为13827万美元，2023年12月31日为57365万美元[15] - 2024年9月28日的资产减值费用为2031万美元，2023年9月30日为78615万美元[15] - 2024年截至9月28日的非GAAP每股收益为0.33美元，2023年截至9月30日的非GAAP每股收益为(0.07)美元[26] - 报告的GAAP毛利为241,892万美元，GAAP毛利率为64.2%[26] - 报告的GAAP运营费用为314,598万美元，运营损失为82,890万美元[26] - 非GAAP毛利为280,038万美元，非GAAP毛利率为74.3%[26] - 2024年截至9月28日的调整后EBITDA为316,822万美元，2023年截至9月30日的调整后EBITDA为234,979万美元[30] 业务动态 - 宣布以2500万美元的价格出售先进康复业务，并可能获得2000万美元的额外收益[4] - 公司定义的有机收入增长为排除收购和剥离影响后的收入增长[29]

Bioventus (BVS) came out with quarterly earnings of $0.06 per share, in line with the Zacks Consensus Estimate. This compares to earnings of $0.05 per share a year ago. These figures are adjusted for non-recurring items.A quarter ago, it was expected that this company would post earnings of $0.07 per share when it actually produced earnings of $0.19, delivering a surprise of 171.43%.Over the last four quarters, the company has surpassed consensus EPS estimates three times.Bioventus, which belongs to the Zac ...

Exhibit 99.1 Bioventus Reports Third Quarter Financial Results • Q3 Revenue Advanced by 15.0%, Fourth Straight Quarter of Double Digit Organic* Growth • Q3 Gross Margin Expanded 200 bps • Q3 Cash from Operations of $10.3 million, an Increase of $18.6 million Compared to Previous Year DURHAM, NC – November 5, 2024 – Bioventus Inc. (Nasdaq: BVS) ("Bioventus" or the "Company"), a global leader in innovations for active healing, today reported financial results for the three and nine months ended September 28, ...

Q3 Revenue Advanced by 15.0%, Fourth Straight Quarter of Double Digit Organic* GrowthQ3 Gross Margin Expanded 200 bpsQ3 Cash from Operations of $10.3 million, an Increase of $18.6 million Compared to Previous Year DURHAM, N.C., Nov. 05, 2024 (GLOBE NEWSWIRE) -- Bioventus Inc. (Nasdaq: BVS) ("Bioventus" or the "Company"), a global leader in innovations for active healing, today reported financial results for the three and nine months ended September 28, 2024. “We delivered strong financial results in the thi ...

The Medical group has plenty of great stocks, but investors should always be looking for companies that are outperforming their peers. Bioventus (BVS) is a stock that can certainly grab the attention of many investors, but do its recent returns compare favorably to the sector as a whole? By taking a look at the stock's year-to-date performance in comparison to its Medical peers, we might be able to answer that question.Bioventus is one of 1024 companies in the Medical group. The Medical group currently sits ...

Bioventus (BVS) is expected to report third-quarter 2024 earnings next month. The Zacks Consensus Estimate for sales and earnings is pegged at $132.6 million and 6 cents per share, respectively.Estimates for Bioventus’ 2024 and 2025 earnings per share (EPS) have remained consistent in the past 60 days at 40 and 45 cents, respectively. The company delivered an earnings surprise of 171.43% in the last reported quarter. Image Source: Zacks Investment ResearchBVS’ Earnings Surprise HistoryThe company’s earnings ...

DURHAM, N.C., Oct. 29, 2024 (GLOBE NEWSWIRE) -- Bioventus Inc. (Nasdaq: BVS) (“Bioventus” or the “Company”), a global leader in innovations for active healing, today announced that it will report financial results for the third quarter of fiscal year 2024 before the market opens on Tuesday, November 5, 2024. The Company’s management will host a conference call at 8:30 a.m. Eastern Time that same day to discuss the results and provide a business update. To participate in the conference call, dial 1-833-636-0 ...

Shares of Bioventus (BVS) have surged 73% in the past three months, significantly outperforming the industry’s 1.3% growth. The stock has outperformed the sector and the S&P 500 during the same period. BVS' shares are also trading above the 50-day and 200-day moving averages.BVS Stock Outperforms Industry, Sector & S&P 500 Image Source: Zacks Investment ResearchThis uptick in stock price was triggered by the company’s encouraging sales performance across its business segments, especially the Pain Treatments ...

The stock price of Bioventus (BVS) has more than doubled in the past six months. This upside can be attributed to the encouraging sales performance across its business segments, based on which management raised the 2024 guidance twice this year. In the past six months, BVS stock significantly outperformed the industry's 5.1% rise. The stock has also outperformed the sector and the S&P 500 during the same period. BVS shares are also trading above the 50-day and 200-day moving averages. BVS Stock Outperforms ...